Abstract:Background Magnetic resonance imaging (MRI) is the best biomarker of inflammatory disease activity in relapsing remitting Multiple Sclerosis (RRMS) so far but the association with disability is weak. Appearance of new MRI-lesions is used to evaluate response to immunotherapies in individual patients as well as being the most common primary outcome in phase-2 trials. Measurements of brain atrophy show promising outcomes in natural cohort studies and some phase-2 trials. From a theoretical perspective they might represent irreversible neurodegeneration and be more closely associated with disability. However, these atrophy measurements are not yet established as prognostic factors in real-life clinical routine. High field MRI has improved image quality and resolution and new methods to measure atrophy dynamics have become available. Objective To investigate the predictive value of MRI classification criteria in to high/low atrophy and inflammation groups, and to explore predictive capacity of two consecutive routine MRI scans for disability progression in RRMS in a real-life prospective cohort. Methods 82 RRMS-patients (40 untreated, 42 treated with immunotherapies, mean age 40 years, median Expanded Disability Status Scale (EDSS) of 2, underwent two clinically indicated MRI scans (3 Tesla) within 5–14 months, and EDSS assessment after a mean of 3.0 (1.5–4.2) years. We investigated the predictive value of predefined classifications in low/high inflammatory and atrophy groups for EDSS progression (≥1.5 if baseline EDSS = 0, ≥1.0 if baseline EDSS <5, ≥0.5 for other) by chi-square tests and by analysis of variance (ANOVA). The classifications were based on current scientific or clinical recommendation (e.g., treatment response criteria). Brain atrophy was assessed with three different methods (SIENA, SIENAX, and FreeSurfer). Post-hoc analyses aimed to explore clinical data and dynamics of MRI outcomes as predictors in multivariate linear and logit models. Results Progression was observed in 24% of patients and was independent from treatment status. None of the predefined classifications were predictive for progression. Explorative post-hoc analyses found lower baseline EDSS and higher grey matter atrophy (FreeSurfer) as best predictors ( R 2 = 0.29) for EDSS progression and the accuracy was overall good (Area under the curve = 0.81). Conclusion Beside EDSS at baseline, short-term grey matter atrophy is predictive for EDSS progression in treated and untreated RRMS. The development of atrophy measurements for individual risk counselling and evaluation of treatment response seems possible, but needs further validation in larger cohorts. MRI-atrophy estimates from the FreeSurfer toolbox seem to be more reliable than older methods.

An update on the role of magnetic resonance imaging in predicting and monitoring multiple sclerosis progression

Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis

Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies

Application and Progress of Magnetic Resonance Imaging in Diagnosis of Pediatric Tumors

Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review

The Role of Advanced Magnetic Resonance Imaging Sequences in Multiple Sclerosis

Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis

Advances in brain imaging in multiple sclerosis

An Algorithm to Predict the Need for Magnetic Resonance Imaging to Support Disease Monitoring in Multiple Sclerosis

MRI Prognostic Factors in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Antibody Disease

Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?

Emerging Perspectives on MRI Application in Multiple Sclerosis: Moving from Pathophysiology to Clinical Practice

Current Methods of Magnetic Resonance for Noninvasive Assessment of Molecular Aspects of Pathoetiology in Multiple Sclerosis

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting

A Radiomic "Warning Sign" of Progression on Brain MRI in Individuals with MS

Magnetic Resonance Imaging Studies of Neurodegenerative Disease: from Methods to Translational Research

Understanding the Pathophysiology and Magnetic Resonance Imaging of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis

A Comparison of Magnetic Resonance Imaging Methods to Assess Multiple Sclerosis Lesions: Implications for Patient Characterization and Clinical Trial Design

Use of Magnetic Resonance Imaging and Artificial Intelligence in Studies of Diagnosis of Parkinson’s Disease

Typical and Emerging Diagnostic MRI Features in Multiple Sclerosis